Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wubie Huangui is a Traditional Chinese Medicine (TCM) compound developed by Jiangsu Kanion Pharmaceutical for the treatment of premature ovarian insufficiency (POI). Formulated as a capsule, it is designed to tonify the kidney and nourish the blood, addressing the underlying pathology of POI according to TCM principles. The drug aims to restore ovarian function, regulate the hypothalamic-pituitary-ovarian (HPO) axis, and improve serum levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), and anti-Müllerian hormone (AMH). Clinical research indicates that Wubie Huangui may also inhibit the apoptosis of ovarian granulosa cells, thereby preserving the ovarian follicle pool and improving fertility outcomes in affected women.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on wubie huangui.